January/February #169 : Cure Watch

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Till Death Do Us Part

Southern Discomfort

Crash-Test Smarties

We Hear You

And We Quote

Adherence Counts

Cure Watch

Losing Face Filler

Savvy Survivor

Higher Education

Prison Breaks

Viewer Discretion Advised

Spotlight: Teen Sex

Aiding Black Power


Heartland Hero


Editor's Letter

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

Scroll down to comment on this story.

email print

January / February 2011

Cure Watch

HDAC Inhibitors

Researchers are training their microscopes on ways to eradicate—not just control—HIV, maybe allowing positive people to avoid a lifetime of HIV meds. One promising experimental technique is the use of HDAC (histone deacetylase) inhibitors.

Even when meds successfully suppress HIV in the bloodstream to undetectable, latent virus lurks in other cells, ready to emerge and reestablish an active infection. Drugs can’t suppress latent HIV, so scientists have to determine how it manages to isolate itself for so long.

The enzyme HDAC helps HIV hide. Or, as David Margolis, MD, of University of North Carolina at Chapel Hill, explains, “HIV ends up as latent virus in a resting cell by accident, and it doesn’t like to be there—like a sprinter whose shoes are untied. Several obstacles keep it from getting out.” HDAC creates one of these. Inhibit HDAC, the theory goes, and then the virus can get moving out of the cells—and meds can attack it.

Some drugs already in use inhibit HDAC. Margolis is studying one, the cancer drug Zolinza (vorinostat). Earlier trials of another HDAC inhibitor, the seizure drug Depakote (valproic acid), were only partly successful, Margolis says. “Valproic didn’t work in a majority of people, but several responded, with declines in resting HIV.” Like HIV combo therapy, combining several HDAC inhibitors that attack the target in different ways might work; if so, valproic acid might make a comeback on a team. But Margolis hopes Zolinza will be effective alone.

A possible hurdle: HDAC inhibitors have a rep for promoting cancer (through genetic changes). But in testing, Margolis says, Zolinza didn’t seem to do this: “[The researchers] never saw mutation.”

Search: HDAC, cure, latent, infection, cancer drug, Zolinza

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.